Study: New drug candidate reduced brain inflammation, protected against cognitive decline in Alzheimer’s mouse model

brain

An anti-inflammatory drug candidate, known as 3,6′-dithiopomalidomide (DP) and designed by researchers at the National Institute on Aging (NIA), protected lab mice against cognitive decline by reducing brain inflammation. An international research team led by the NIA scientists has published their findings in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association.

The study results provide new evidence that brain inflammation—which occurs decades before Alzheimer’s symptoms are noticeable—is a key neuropathological pathway of interest in efforts to find potential treatments for Alzheimer’s.

Source: Read Full Article

Related posts:
  1. ‘Supply is a challenge’: Half of Cannabis NB stores closed on Monday morning due to cannabis shortages
  2. Should Calgary bring fluoridated water back? Council expected to review new study this month
  3. World’s first agreed-upon guidance for people with diabetes to exercise safely
  4. New immune system findings could accelerate ‘on-demand’ production of antibody-based drugs and vaccines
  5. Triaging Neurocognitive Screening After SARS-CoV-2 Infection